Page last updated: 2024-11-08

fustin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

fustin : A dihydroflavonol that is the 2,3-dihydro derivative of fisetin. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

tetrahydroxyflavanone : A hydroxyflavanone with atleast four hydroxy substituents. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5317435
CHEMBL ID470267
SCHEMBL ID13640269
MeSH IDM0513665

Synonyms (50)

Synonym
tetrahydroxyflavanone
nsc-59264
dihydrofisetin
4h-1-benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-2,3-dihydro-3,7-dihydroxy-, trans-
C01378
20725-03-5
2,3-dihydrofisetin
fustin
CHEMBL470267 ,
(2r,3r)-2-(3,4-dihydroxyphenyl)-3,7-dihydroxy-2,3-dihydrochromen-4-one
AC1NSVLG ,
flavanone, 3,3',4',7-tetrahydroxy- (van)
3,7,3',4'-tetrahydroxyflavanone
unii-4994c1x19a
trans-2-(3,4-dihydroxyphenyl)-2,3-dihydro-3,7-dihydroxy-4-benzopyrone
4994c1x19a ,
einecs 243-989-6
nsc 59264
SCHEMBL13640269
unii-c308qr79ue
(2r,3r)-2-(3,4-dihydroxyphenyl)-2,3-dihydro-3,7-dihydroxy-4h-1-benzopyran-4-one
4382-36-9
4h-1-benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-2,3-dihydro-3,7-dihydroxy-, (2r,3r)-
(+)-fustin
fustin, (+)-
fustin (2r,3r)-form [mi]
2,3-trans-fustin
4h-1-benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-2,3-dihydro-3,7-dihydroxy-, (2r-trans)-
C308QR79UE ,
flavanone, 3,3',4',7-tetrahydroxy-, (+)-
surecn13640269
(2r,3r)-2-(3,4-dihydroxyphenyl)-3,7-dihydroxy-chroman-4-one
ambap20725-03-5
4h-1-benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-2,3-dihydro-3,7-dihydroxy-, (2r,3r)-rel-
fustin, (+/-)-
fustin [mi]
trans-(+/-)-3,3',4',7-tetrahydroxyflavanone
(+/-)-fustin
4h-1-benzopyran-4-one,2-(3,4-dihydroxyphenyl)-2,3-dihydro-3,7-dihydroxy-,(2r,3r)-rel-
mfcd00075647
3,7,3',4'-tetrahydroxy-flavanon
AKOS032948206
Q5510352
FS-9541
(2r,3r)-2-(3,4-dihydroxyphenyl)-3,7-dihydroxychroman-4-one
DTXSID401136309
DTXSID70871986
HY-N8376
CS-0143760
flavanone, 3,3',4',7-tetrahydroxy-(van)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Pathways (1)

PathwayProteinsCompounds
Flavonoid Biosynthesis1150

Bioassays (7)

Assay IDTitleYearJournalArticle
AID1424433Cytotoxicity in human K562 cells by SRB assay2017European journal of medicinal chemistry, Dec-15, Volume: 142Recent discoveries of anticancer flavonoids.
AID338027Inhibition of beef heart mitochondrial NADH oxidase assessed per mg of protein
AID336952Inhibition of bovine thymocytes protein tyrosine kinase assessed as angiotensin 1 phosphorylation
AID400607Inhibition of procoagulant activity in monocyte from human blood assessed as counteraction of IL1-induced tissue factor expression at 10 uM after 18 hrs measured as microunits of tissue factor/10'5 cells1996Journal of natural products, Mar, Volume: 59, Issue:3
Ability of different flavonoids to inhibit the procoagulant activity of adherent human monocytes.
AID338974Inhibition of cow milk xanthine oxidase at 50 ug/mL
AID1130099Inhibition of human aromatase using androstenedione as substrate assessed as remaining estrone level at 10 uM after 30 mins by LC-MS/MS analysis relative to control2014Bioorganic & medicinal chemistry letters, Apr-01, Volume: 24, Issue:7
Inhibitory effect of Rhus verniciflua Stokes extract on human aromatase activity; butin is its major bioactive component.
AID358173Inhibition of p40 tyrosine kinase1992Journal of natural products, Nov, Volume: 55, Issue:11
Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (19)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (5.26)18.7374
1990's3 (15.79)18.2507
2000's2 (10.53)29.6817
2010's10 (52.63)24.3611
2020's3 (15.79)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (9.09%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other20 (90.91%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]